Goldman Sachs Group Inc Zentalis Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 456,393 shares of ZNTL stock, worth $670,897. This represents 0.0% of its overall portfolio holdings.

Number of Shares

456,393

Previous 456,393 -0.0%

Holding current value

$670,897

Previous $725,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$1.59 - $3.24 $734,125 - $1.5 Million	-461,714 Reduced 50.29%	456,393 $725,000
Q4 2024 Feb 11, 2025	BUY	$2.7 - $4.03 $766,916 - $1.14 Million	284,043 Added 44.8%	918,107 $2.78 Million
Q3 2024 Nov 14, 2024	BUY	$2.9 - $4.57 $42,951 - $67,686	14,811 Added 2.39%	634,064 $2.33 Million
Q2 2024 Aug 13, 2024	BUY	$4.09 - $16.13 $1.17 Million - $4.63 Million	287,253 Added 86.52%	619,253 $2.53 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $423,658 - $645,072	39,119 Added 13.36%	332,000 $5.23 Million
Q4 2023 Feb 13, 2024	BUY	$9.84 - $20.13 $685,060 - $1.4 Million	69,620 Added 31.18%	292,881 $4.44 Million
Q3 2023 May 14, 2024	SELL	$19.63 - $28.29 $1.37 Million - $1.97 Million	-69,620 Reduced 23.77%	223,261 $4.48 Million
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $10 Million - $14.4 Million	-510,316 Reduced 69.57%	223,261 $4.48 Million
Q2 2023 May 14, 2024	BUY	$17.41 - $30.05 $9.22 Million - $15.9 Million	529,631 Added 259.69%	733,577 $20.7 Million
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $9.22 Million - $15.9 Million	529,631 Added 259.69%	733,577 $20.7 Million
Q1 2023 May 14, 2024	SELL	$16.14 - $24.94 $3.01 Million - $4.65 Million	-186,436 Reduced 47.76%	203,946 $3.51 Million
Q1 2023 May 11, 2023	SELL	$16.14 - $24.94 $3.01 Million - $4.65 Million	-186,436 Reduced 47.76%	203,946 $3.51 Million
Q4 2022 May 14, 2024	BUY	$18.07 - $25.6 $940,543 - $1.33 Million	52,050 Added 15.38%	390,382 $7.86 Million
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $940,543 - $1.33 Million	52,050 Added 15.38%	390,382 $7.86 Million
Q3 2022 May 14, 2024	SELL	$20.23 - $31.73 $1.2 Million - $1.88 Million	-59,238 Reduced 14.9%	338,332 $7.33 Million
Q3 2022 Nov 10, 2022	SELL	$20.23 - $31.73 $1.2 Million - $1.88 Million	-59,238 Reduced 14.9%	338,332 $7.33 Million
Q2 2022 May 14, 2024	BUY	$17.91 - $52.25 $1.87 Million - $5.47 Million	104,689 Added 35.74%	397,570 $11.2 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $2.37 Million - $6.91 Million	132,324 Added 49.89%	397,570 $11.2 Million
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $5.15 Million - $10 Million	123,877 Added 87.63%	265,246 $12.2 Million
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $5.95 Million - $7.54 Million	-88,972 Reduced 38.63%	141,369 $11.9 Million
Q3 2021 Nov 10, 2021	BUY	$46.83 - $73.5 $10.8 Million - $16.9 Million	230,341 New	230,341 $15.4 Million

Others Institutions Holding ZNTL

# of Institutions

140

Shares Held

60.7M

Call Options Held

7.9K

Put Options Held

42.5K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $83.8M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Zentalis Pharmaceuticals, Inc. Transaction History